<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04349358</url>
  </required_header>
  <id_info>
    <org_study_id>2019-003627-38</org_study_id>
    <nct_id>NCT04349358</nct_id>
  </id_info>
  <brief_title>FCH vs FDG PET/CT in Detection of Lesions in Patients With Multiple Myeloma (MIM)</brief_title>
  <acronym>MIM</acronym>
  <official_title>18F-Fluorocholine (FCH) Versus 18F-Fluorodesoxyglucose (FDG) PET/CT in Detection of Lesions in Patients With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Georges Francois Leclerc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Georges Francois Leclerc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hybrid positron emission tomography/computed tomography (PET/CT) has now become available to
      detect tumors in patients with multiple myeloma. The radioactive glucose
      18F-fluorodeoxyglucose (FDG) is the most widely used tracer but findings suggest that PET/CT
      reveal more lesions when using FCH.

      In this study, FDG is compared with a more recent metabolic tracer, 18F-fluorocholine (FCH),
      for the detection of multiple myeloma lesions at time of initial extension assessment.

      The principal objective of this sudy is to compare the number of suspected hypermetabolic
      foci of myeloma detected by 18F-fluorocholine PET and by 18F-fluorodeoxyglucose PET during
      the initial extension assessment.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">August 2029</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of hypermetabolic foci of myeloma detected by FCH PET versus by FDG PET during the initial extension assessment</measure>
    <time_frame>before maintenance treatment</time_frame>
    <description>PET/CT</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>FDG and FCH PET/CT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>FDG and FCH PET/CT</intervention_name>
    <description>during the initial myeloma check-up : FDG and FCH PET/CT exams (maximum 21 days after inclusion)
just before maintenance treatment, respecting a minimum interval of 2 weeks after the last course of chemotherapy : FDG and FCH PET/CT exams</description>
    <arm_group_label>FDG and FCH PET/CT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with initial diagnosis of multiple myeloma has just been established

          -  Therapeutic indication and eligible for a CSH autograft.

          -  Status ECOG 0, 1 or 2

          -  Age ≥ 18 and &lt; 75 ans years

          -  Effective contraception for women

          -  Informed consent signed

          -  Patient able to lie flat for 30 minutes

          -  Patient affiliated to a social security scheme

        Exclusion Criteria:

          -  Patient diagnosed with a diagnosis of MGUS (Monoclonal Gammapathy of Undetermined
             Significance = monoclonal gammopathy of undetermined significance), indolent myeloma
             (&quot;smoldering myeloma&quot;), non-secreting myeloma or recurrent myeloma,

          -  Patient already under treatment for myeloma.

          -  Patient not eligible for intensive treatment followed by a CSH autograft.

          -  Patient with concomitant neoplasia

          -  Patient with a history of hematological or solid neoplasia, except if it is a basal
             cell carcinoma of the skin or an adenocarcinoma in situ of the uterine cervix.

          -  Patient with a history of sarcoidosis

          -  Uncontrolled diabetes.

          -  Patient treated with long-term corticosteroids

          -  Patient being treated with hematopoietic growth factors

          -  Patient in sepsis.

          -  Claustrophobic patient.

          -  Refusal of patient consent.

          -  Pregnant or lactating woman.

          -  Women of childbearing potential without effective contraception.

          -  Person deprived of liberty or under guardianship

          -  Impossibility to submit to the medical follow-up of the trial for geographic, social
             or psychological reasons.

          -  History of allergic reaction attributed to 18F-fluorodeoxyglucose or to
             18F-fluorocholine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Emilie REDERSTORFF</last_name>
    <phone>03 43 34 81 16</phone>
    <email>erederstorff@cgfl.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jean FONTAN</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Clement DROUET</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Denis CAILLOT</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 10, 2020</study_first_submitted>
  <study_first_submitted_qc>April 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2020</study_first_posted>
  <last_update_submitted>April 15, 2020</last_update_submitted>
  <last_update_submitted_qc>April 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PET/CT</keyword>
  <keyword>FDG</keyword>
  <keyword>Fluorocholine (18F) FCH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

